Adamas Signs CRADA With US Navy

Adamas Pharmaceuticals has entered into a co-operative R&D agreement (CRADA) with the US Naval Health Research Center. The deal is for preclinical studies evaluating Adamas’ triple combination antiviral drug (TCAD) therapy for influenza A, including new influenza A/H1N1.

Under the CRADA, the US Naval Health Research Center will conduct comparative tests of Adamas’ TCAD therapy against various strains of the influenza A virus, including seasonal influenza (H1N1, H3N2), avian influenza (H5N1), and novel influenza A/H1N1.

The purpose of these studies is to assess the in-vitro activity of TCAD therapy against various pathogenic strains of the influenza A virus, as well as to compare the in-vitro activity of TCAD therapy to other pharmaceutical agents when used alone or in double combination.

Reportedly, the data from these experiments will be used to advance the development of Adamas’ TCAD therapy as a potential broad-spectrum antiviral therapy for serious infections caused by influenza A viruses.

Gregory Went, chairman and CEO of Adamas, said: Collaborating with the US Naval Health Research Center, with its seminal work in discovering the novel influenza A/H1N1 virus, will significantly advance Adamas’ efforts to develop TCAD therapy in response to the influenza pandemic. We look forward to partnering with the Naval Health Research Center to generate data that further support the potential use of TCAD therapy for the military, healthcare workers and general public when faced with the global threat of influenza A outbreaks.